Krystal Biotech, Inc. (NASDAQ:KRYS) Q3 2024 Earnings Call Transcript November 4, 2024 Krystal Biotech, Inc. beats earnings expectations. Reported EPS is $0.909, expectations were $0.9. Operator: Thank ...
It's the best colorway in our opinion, and it's been sold out at Anthropologie for MONTHS — so now's the time to grab a pair ...
First, we are continuing to sign new research customers at well-respected hospitals ... Expand: Democratize testing through FDA-cleared VitaGraft+ kit 4. Obtain regulatory clearance for clinical use: ...
United Kingdom, London, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Oil and gas fields and the upsurge in oil and gas exploration and ...
Similar to our Phase 1 study, which enabled a move from IND clearance to clinical data in the course of a few months, we ...
Veritone, Inc. (NASDAQ:VERI), a leader in designing human-centered AI solutions, today reported results for the third quarter ended September 30, 2024. "The divestiture ...
Third-quarter 2024 sales of $2.4 billion, up 6% on a reported and constant currency 1 (cc) basis Third-quarter 2024 diluted EPS of $0.53, up 29%, or 32% cc; core diluted EPS 2 of $0.81, up 23%, or 25% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback